Efficacy and safety of daptomycin in patients with renal impairment: A multicenter retrospective analysis

Pharmacotherapy

Volumn 34, Issue 6, 2014, Pages 582-589

  Kullar, Ravina ^a,b   McClellan, Ian ^b   Geriak, Matthew ^c   Sakoulas, George ^c,d  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c SHARP MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

daptomycin; MRSA infections; renally impaired

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; ANTIINFECTIVE AGENT; CREATININE;

ADULT; AGED; BACTERIAL STRAIN; CASE STUDY; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAM POSITIVE INFECTION; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIDDLE AGED; NEPHROTOXICITY; NONHUMAN; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; ANTIBIOTIC RESISTANCE; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; URINE;

AGED; ANTI-BACTERIAL AGENTS; CREATINE KINASE; CREATININE; DAPTOMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84902146006     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1413     Document Type: Conference Paper

References (30)

1. Rybak MJ,. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 (Suppl. 1): S35-9.
2. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
3. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
4. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
5. Streit JM, Jones RN, Sader HS,. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53: 669-74.
6. Anastasiou DM, Thorne GM, Luperchio SA, et al. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006; 28: 385-8.
7. Cubist Pharmaceuticals, Inc. Cubicin (daptomycin for injection) product information. Lexington, MA; 2013.
8. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
9. Vilay AM, Grio M, Depestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011; 39: 19-25.
10. Kielstein JT, Eugbers C, Bode-Boeger SM, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2010; 25: 1537-41.
11. Benziger DP, Pertel PE, Donovan J, et al. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol 2011; 75: 63-9.
12. Mueller BA, Crompton JA, Donovan BJ, Yankalev S, Lamp KC,. Safety of daptomycin in patients receiving hemodialysis. Pharmacotherapy 2011; 31: 665-672.
13. Moise PA, Amodio-Groton M, Rashid M, et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 2013; 57: 1192-200.
14. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-8.
16. Patel N, Cardone K, Grabe DW, et al. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrob Agents Chemother 2011; 55: 1677-83.
17. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
18. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011; 31: 527-36.
19. Moise PA, Hershberger E, Amodio-Groton MI, et al. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 2009; 43: 1211-9.
20. Boucher HW, Sakoulas G,. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45: 601-8.
21. Hayden MK, Rezai K, Hayes RA, et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 5285-7.
22. Skiest DJ,. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44: 655-6.
23. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52: 269-78.
24. Julian K, Kosowska-Shick K, Whitener C, et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 2007; 51: 3445-8.
25. Mishra NN, Bayer AS, Moise PA, et al. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis 2012; 206: 1160-7.
26. Sakoulas G, Eliopoulos GM, Fowler VG Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49: 2687-92.
27. Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.
28. Gasche Y, Pascual M, Suter PM, et al. Complement depletion during haemofiltration with polyacrilonitrile membranes. Nephrol Dial Transplant 1996; 11: 117-9.
29. Koller H, Hochegger K, Zlabinger GJ, et al. Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system. Nephrol Dial Transplant 2004; 19: 3104-11.
30. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-92.